User login
Key clinical point: Pretreatment albumin-bilirubin (ALBI) score and radiation dose on the nontumor section of the liver are independent predictive factors for post-transarterial radioembolization (TARE) hepatic decompensation in patients with hepatocellular carcinoma (HCC).
Major finding: Multivariate analysis revealed ALBI score at baseline (adjusted odds ratio [aOR] 6.425; P = .005) and radiation dose on the nontumor section of the liver (aOR 1.072; P = .011) to be independent risk factors for the development of hepatic decompensation after TARE.
Study details: Findings are from a single-center retrospective observational study that included 61 patients with HCC who underwent TARE and thereafter did (n = 17) or did not (n = 44) develop hepatic decompensation.
Disclosures: This study was conducted with no specific funding. Some authors declared serving as consultants, advisors, or speakers for various organizations.
Source: Reincke M et al. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun. 2022 (Sep 5). Doi: 10.1002/hep4.2072
Key clinical point: Pretreatment albumin-bilirubin (ALBI) score and radiation dose on the nontumor section of the liver are independent predictive factors for post-transarterial radioembolization (TARE) hepatic decompensation in patients with hepatocellular carcinoma (HCC).
Major finding: Multivariate analysis revealed ALBI score at baseline (adjusted odds ratio [aOR] 6.425; P = .005) and radiation dose on the nontumor section of the liver (aOR 1.072; P = .011) to be independent risk factors for the development of hepatic decompensation after TARE.
Study details: Findings are from a single-center retrospective observational study that included 61 patients with HCC who underwent TARE and thereafter did (n = 17) or did not (n = 44) develop hepatic decompensation.
Disclosures: This study was conducted with no specific funding. Some authors declared serving as consultants, advisors, or speakers for various organizations.
Source: Reincke M et al. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun. 2022 (Sep 5). Doi: 10.1002/hep4.2072
Key clinical point: Pretreatment albumin-bilirubin (ALBI) score and radiation dose on the nontumor section of the liver are independent predictive factors for post-transarterial radioembolization (TARE) hepatic decompensation in patients with hepatocellular carcinoma (HCC).
Major finding: Multivariate analysis revealed ALBI score at baseline (adjusted odds ratio [aOR] 6.425; P = .005) and radiation dose on the nontumor section of the liver (aOR 1.072; P = .011) to be independent risk factors for the development of hepatic decompensation after TARE.
Study details: Findings are from a single-center retrospective observational study that included 61 patients with HCC who underwent TARE and thereafter did (n = 17) or did not (n = 44) develop hepatic decompensation.
Disclosures: This study was conducted with no specific funding. Some authors declared serving as consultants, advisors, or speakers for various organizations.
Source: Reincke M et al. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun. 2022 (Sep 5). Doi: 10.1002/hep4.2072